Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapeutics for serious and rare diseases, with a primary focus on autoimmune conditions. Operating out of Waltham, Massachusetts, the company specializes in engineering monoclonal antibodies for the treatment of thyroid eye disease (TED). Its lead clinical programs include veligrotug, an intravenously administered antibody, and elegrobart, a subcutaneously administered formulation, both of which target the insulin-like growth factor-1 receptor (IGF-1R). Beyond its TED franchise, Viridian is advancing a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed to treat a broader range of antibody-mediated autoimmune diseases. The company leverages its expertise in protein engineering to create differentiated therapies for previously validated drug targets, aiming to improve efficacy and patient convenience. Viridian conducts its clinical trials globally and partners with contract manufacturing organizations to support its development pipeline.
